BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 27941878)

  • 1. The molecular mechanisms underlying the ERα-36-mediated signaling in breast cancer.
    Omarjee S; Jacquemetton J; Poulard C; Rochel N; Dejaegere A; Chebaro Y; Treilleux I; Marangoni E; Corbo L; Romancer ML
    Oncogene; 2017 May; 36(18):2503-2514. PubMed ID: 27941878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Benzopyran derivative CDRI-85/287 induces G2-M arrest in estrogen receptor-positive breast cancer cells via modulation of estrogen receptors α- and β-mediated signaling, in parallel to EGFR signaling and suppresses the growth of tumor xenograft.
    Saxena R; Fatima I; Chandra V; Blesson CS; Kharkwal G; Hussain MK; Hajela K; Roy BG; Dwivedi A
    Steroids; 2013 Nov; 78(11):1071-86. PubMed ID: 23891847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Annonacin induces cell cycle-dependent growth arrest and apoptosis in estrogen receptor-α-related pathways in MCF-7 cells.
    Ko YM; Wu TY; Wu YC; Chang FR; Guh JY; Chuang LY
    J Ethnopharmacol; 2011 Oct; 137(3):1283-90. PubMed ID: 21840388
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triptolide inhibits human breast cancer MCF-7 cell growth via downregulation of the ERα-mediated signaling pathway.
    Li H; Pan GF; Jiang ZZ; Yang J; Sun LX; Zhang LY
    Acta Pharmacol Sin; 2015 May; 36(5):606-13. PubMed ID: 25864647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of mitogen-activated protein kinase in estrogen receptor alpha-positive breast cancer cells in vitro induces an in vivo molecular phenotype of estrogen receptor alpha-negative human breast tumors.
    Creighton CJ; Hilger AM; Murthy S; Rae JM; Chinnaiyan AM; El-Ashry D
    Cancer Res; 2006 Apr; 66(7):3903-11. PubMed ID: 16585219
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A hypermethylation strategy utilized by enhancer-bound CARM1 to promote estrogen receptor α-dependent transcriptional activation and breast carcinogenesis.
    Peng BL; Li WJ; Ding JC; He YH; Ran T; Xie BL; Wang ZR; Shen HF; Xiao RQ; Gao WW; Ye TY; Gao X; Liu W
    Theranostics; 2020; 10(8):3451-3473. PubMed ID: 32206101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A novel taspine derivative, HMQ1611, inhibits breast cancer cell growth via estrogen receptor α and EGF receptor signaling pathways.
    Zhan Y; Zhang Y; Liu C; Zhang J; Smith WW; Wang N; Chen Y; Zheng L; He L
    Cancer Prev Res (Phila); 2012 Jun; 5(6):864-73. PubMed ID: 22496388
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MAP kinase/estrogen receptor cross-talk enhances estrogen-mediated signaling and tumor growth but does not confer tamoxifen resistance.
    Atanaskova N; Keshamouni VG; Krueger JS; Schwartz JA; Miller F; Reddy KB
    Oncogene; 2002 Jun; 21(25):4000-8. PubMed ID: 12037682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FGF2 induces breast cancer growth through ligand-independent activation and recruitment of ERα and PRBΔ4 isoform to MYC regulatory sequences.
    Giulianelli S; Riggio M; Guillardoy T; Pérez Piñero C; Gorostiaga MA; Sequeira G; Pataccini G; Abascal MF; Toledo MF; Jacobsen BM; Guerreiro AC; Barros A; Novaro V; Monteiro FL; Amado F; Gass H; Abba M; Helguero LA; Lanari C
    Int J Cancer; 2019 Oct; 145(7):1874-1888. PubMed ID: 30843188
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cooperative action of tamoxifen and c-Src inhibition in preventing the growth of estrogen receptor-positive human breast cancer cells.
    Herynk MH; Beyer AR; Cui Y; Weiss H; Anderson E; Green TP; Fuqua SA
    Mol Cancer Ther; 2006 Dec; 5(12):3023-31. PubMed ID: 17172405
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Estrogen receptor α regulates non-canonical autophagy that provides stress resistance to neuroblastoma and breast cancer cells and involves BAG3 function.
    Felzen V; Hiebel C; Koziollek-Drechsler I; Reißig S; Wolfrum U; Kögel D; Brandts C; Behl C; Morawe T
    Cell Death Dis; 2015 Jul; 6(7):e1812. PubMed ID: 26158518
    [TBL] [Abstract][Full Text] [Related]  

  • 12. p53 inactivation decreases dependence on estrogen/ERK signalling for proliferation but promotes EMT and susceptility to 3-bromopyruvate in ERα+ breast cancer MCF-7 cells.
    Rieber M; Strasberg-Rieber M
    Biochem Pharmacol; 2014 Mar; 88(2):169-77. PubMed ID: 24486524
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The ERα-miR-575-p27 feedback loop regulates tamoxifen sensitivity in ER-positive Breast Cancer.
    Liu SS; Li Y; Zhang H; Zhang D; Zhang XB; Wang X; Yu Y
    Theranostics; 2020; 10(23):10729-10742. PubMed ID: 32929377
    [No Abstract]   [Full Text] [Related]  

  • 14. The proteasome inhibitor Bortezomib (Velcade) as potential inhibitor of estrogen receptor-positive breast cancer.
    Thaler S; Thiede G; Hengstler JG; Schad A; Schmidt M; Sleeman JP
    Int J Cancer; 2015 Aug; 137(3):686-97. PubMed ID: 25530422
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Williams syndrome transcription factor (WSTF) acts as an activator of estrogen receptor signaling in breast cancer cells and the effect can be abrogated by 1α,25-dihydroxyvitamin D
    Lundqvist J; Kirkegaard T; Laenkholm AV; Duun-Henriksen AK; Bak M; Feldman D; Lykkesfeldt AE
    J Steroid Biochem Mol Biol; 2018 Mar; 177():171-178. PubMed ID: 28610873
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MiR-301a-3p Suppresses Estrogen Signaling by Directly Inhibiting ESR1 in ERα Positive Breast Cancer.
    Lettlova S; Brynychova V; Blecha J; Vrana D; Vondrusova M; Soucek P; Truksa J
    Cell Physiol Biochem; 2018; 46(6):2601-2615. PubMed ID: 29763890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. AKT3 regulates ErbB2, ErbB3 and estrogen receptor α expression and contributes to endocrine therapy resistance of ErbB2(+) breast tumor cells from Balb-neuT mice.
    Grabinski N; Möllmann K; Milde-Langosch K; Müller V; Schumacher U; Brandt B; Pantel K; Jücker M
    Cell Signal; 2014 May; 26(5):1021-9. PubMed ID: 24463007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of Gefitinib-mediated reversal of tamoxifen resistance in MCF-7 breast cancer cells by inducing ERα re-expression.
    Zhang X; Zhang B; Liu J; Liu J; Li C; Dong W; Fang S; Li M; Song B; Tang B; Wang Z; Zhang Y
    Sci Rep; 2015 Feb; 5():7835. PubMed ID: 25644501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen Enhances the Cell Viability and Motility of Breast Cancer Cells through the ERα-ΔNp63-Integrin β4 Signaling Pathway.
    Ho JY; Chang FW; Huang FS; Liu JM; Liu YP; Chen SP; Liu YL; Cheng KC; Yu CP; Hsu RJ
    PLoS One; 2016; 11(2):e0148301. PubMed ID: 26845172
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity.
    Santen RJ; Song RX; Zhang Z; Kumar R; Jeng MH; Masamura A; Lawrence J; Berstein L; Yue W
    Endocr Relat Cancer; 2005 Jul; 12 Suppl 1():S61-73. PubMed ID: 16113100
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.